Coeptis Therapeutics Holdings, Inc. WarrantsCOEPW
About: Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
Employees: 7
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
2.11% less ownership
Funds ownership: 4.47% [Q3] → 2.36% (-2.11%) [Q4]
24% less capital invested
Capital invested by funds: $27.4K [Q3] → $20.8K (-$6.61K) [Q4]
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
29% less funds holding
Funds holding: 17 [Q3] → 12 (-5) [Q4]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Research analyst outlook
We haven’t received any recent analyst ratings for COEPW.
Financial journalist opinion
We haven’t received any recent news articles for COEPW.